|Predicted||Bovine, Chicken, Human, Mouse, Monkey|
|Calculated MW||32 KDa|
|Other Names||Protein phosphatase 1 regulatory subunit 1B, DARPP-32, Dopamine- and cAMP-regulated neuronal phosphoprotein, Ppp1r1b|
|Target/Specificity||Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr75 conjugated to KLH.|
|Format||Prepared from rabbit serum by affinity purification via sequential chromatography on phospho- and dephosphopeptide affinity columns.|
|Antibody Specificity||Specific for the ~32k DARPP-32 protein phosphorylated at Thr75. Immunolabeling is blocked by λ-phosphatase treatment.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Phospho-ThrDARPP-32 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DARPP-32 is a dopamine (DA) and cAMP-regulated ~32k phosphoprotein that is associated with dopaminoceptive neurons (Fienberg et al., 1998). The protein inhibits protein phosphatase I when it is phosphorylated on Thr34. In contrast, when DARPP-32 is phosphorylateThr75 the protein acts as an inhibitor of PKA (Bibb et al., 1999). Phosphorylation of DARPP-32 is thougto play a critical role in the regulation of dopaminergic neurotransmission. In addition, the activity of DARPP-32 is also thought to play important roles in the actions of alcohol, caffeine and Prozac® (Maet al., 2002; Lindskog et al., 2002; Svenningsson et al., 2002).
Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC, Jr., Nairn AC, Greengard P (1999) Phosphorylation of DARPP-32 by cdk5 modulates dopamine signalling in neurons. Nature (London) 402:669-671.
Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A. O'Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D,C., Onn, S.P., Grace, A.A., Ouimet, C.C., White, F.G., Hyman, S.E., Surmeier, D.G., Girault, J., Nestler, E.J. and Greengard, P. (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281:838-842.
Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, Fredholm BB, Nairn AC, Greengard P, Fisone G (2002) Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature (London) 418:774-778.
Maldve RE, Zhang TA, Ferrani-Kile K, Schreiber SS, Lippmann MJ, Snyder GL, Feinberg AA, Leslie SW, Gonzales RA, Morrisett RA (2002) DARPP-32 and the regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens. Nature Neurosci 5:641-648.
Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P (2002) Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac®). Proc Natl Acad Sci USA 99:3182-3187.
Michelle Niculescu, Shane A. Perrine, Jonathan S. Miller, Michelle E. Ehrlich, and Ellen M. Unterwald (2008) Trk: A Neuromodulator of Age-Specific Behavioral and Neurochemical Responses to Cocaine in Mice. J. Neurosci., Jan 2008; 28: 1198 - 1207.
If you have any additional inquiries please email technical services at email@example.com.